COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Receives Notice of $250,000 FDA Grant to Fund Confirmatory Trial to Support FDA Approval of Canalevia for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
Jaguar Animal Health receives $250,000 grant from FDA's CVM for Canalevia-CA1 to treat chemotherapy-induced diarrhea in dogs. Company seeks to expand partnership for global commercialization of Canalevia -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Submits Orphan Drug Designation Application to FDA for Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Patients with Breast Cancer with Metastasis Identified by FDA as a Distinct Condition
Jaguar Health's Napo Pharmaceuticals submits orphan drug designation application to FDA for crofelemer in treating diarrhea in adult patients with breast cancer metastasized to the brain, targeting expedited regulatory pathways -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. announces CEO Lisa Conte's virtual presentations at upcoming conferences. The company focuses on developing plant-derived medicines for gastrointestinal distress
